Pipeline
A pipeline of drug candidates that target the peripheral immune system
PROGRAM
EXPLORATORY
PRE-CLINICAL
IND-ENABLING
CLINICAL
STATUS
IBC-Ab002 (anti-PD-L1 mAb) for Alzheimer's disease
Phase 1b trial started May-2023
IBC-Ab002 (anti-PD-L1 mAb) for other tauopathies [indication TBD]
Clinical trial planned to initiate in 2025
Additional Neurodegenerative conditions (undisclosed)
